June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Murine Retinal Development, Morphology and Function in Albinism: Potential Implications for Therapeutic Development
Author Affiliations & Notes
  • Helena helenalee100@yahoo.co.uk Lee
    Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  • Jennifer Scott
    Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  • Helen Griffiths
    Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  • Andrew J Lotery
    Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  • Footnotes
    Commercial Relationships   Helena Lee, None; Jennifer Scott, None; Helen Griffiths, None; Andrew Lotery, None
  • Footnotes
    Support  Academy of Medical Sciences Starter Grant for Clinical Lecturers; University of Southampton Research Management Committee Grant; Gift of Sight Starter Grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5570. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Helena helenalee100@yahoo.co.uk Lee, Jennifer Scott, Helen Griffiths, Andrew J Lotery; Murine Retinal Development, Morphology and Function in Albinism: Potential Implications for Therapeutic Development. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5570.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Albinism is a disorder of melanin biosynthesis characterised by abnormal retinal development & visual impairment, for which there is a paucity of effective treatments. Preclinical studies in murine albinism models are essential to develop novel therapeutics. It is necessary to develop a detailed understanding of in-vivo retinal development, morphology & function prior to performing proof of concept treatment studies. In this study, we characterise the retinal phenotype of the C57BL/6J-c2J null mouse model of oculocutaneous albinism (OCA).

Methods : We obtained 53 mixed cross-sectional and longitudinal in-vivo optical coherence tomography (OCT) and electroretinography (ERG) examinations from 9 C57BL/6J-c2J OCA mice at 4, 5, 6, 8, 12 & 16 weeks of age, which were compared to 110 examinations from 11 C57Bl/6J control mice. Retinal layer segmentation was performed using Bioptigen InVivoVue Diver 2.4 software. Generalised linear mixed regression modelling was used to analyse group differences.

Results : In comparison to control mice, there was evidence of a significant reduction in the combined ganglion cell & inner plexiform layer (p<0.01) and retinal pigment epithelium (p<0.0001) thickness measurements in OCA mice. Interestingly, the photoreceptor inner segment (IS) appeared to be significantly thicker in OCA (p<0.0001). We observed a decrease in photoreceptor IS, outer segment (OS) and end-tips (ETPRS) thickness between four and six weeks of age, followed by an increase in both groups. The magnitude of increase was greater in control mice, resulting in a significantly greater OS thickness at eight (p<0.01), twelve (p<0.0001) & sixteen (p<0.0001) weeks of age, ETPRS thickness at twelve (p<0.01) & sixteen (p<0.01) weeks of age, and elimination of the group differences in IS thickness by sixteen weeks. This corresponded with significant reductions in A (p<0.05) & B-wave (p<0.01) wave amplitudes on ERG in OCA, with mean (SD) A & B-wave amplitudes of -98.3 (62.9) µV & 219.1 (90.1) µV in OCA and -113.0 (66.5) µV & 261.8 (98.9) µV in control mice, respectively.

Conclusions : We have characterised the retinal phenotype of the C57BL/6J-c2J null mouse model of OCA, and identified several OCT biomarkers, which could be used to monitor in vivo murine responses to potential drug treatment(s). This is important for future translational studies & therapeutic development in albinism.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×